Hyperfine (HYPR) vs Pulmonx (LUNG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pulmonx (LUNG) has outperformed Hyperfine (HYPR) over the past year, gaining 1.7% versus a loss of 55.0%. Over five years, HYPR leads with a -90.5% price change compared with -95.5% for LUNG. Hyperfine is the larger company by market cap ($99.7 million vs $77.7 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HYPR | LUNG |
|---|---|---|
| Share price | $0.9401 | $1.81 |
| Market cap | $99.70M | $77.74M |
| 1-day change | +10.73% | -1.63% |
| YTD return | -3.97% | -18.10% |
| 1-year return | -55.02% | +1.69% |
| 5-year return | -90.54% | -95.45% |
| EPS (TTM) | $-0.37 | $-1.19 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.22 | $2.89 |
| 52-week low | $0.754 | $1.13 |
| Distance from 52-week high | -57.65% | -37.37% |
| Analyst consensus | none | none |
| Avg. price target upside | +115.93% | +87.85% |
| Average volume | 611.89K | 477.26K |
| Shares outstanding | 90.99M | 42.95M |
| Employees | 102 | 296 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed HYPR by 56.7 percentage points over the past year.
About Hyperfine
HYPR stock →Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.
Healthcare · Medical Devices · 102 employees
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Healthcare · Medical Devices · 296 employees
HYPR vs LUNG FAQ
Which is bigger, Hyperfine or Pulmonx?
Hyperfine (HYPR) is larger, with a market capitalization of $99.70M compared with $77.74M for Pulmonx (LUNG).
Which stock has performed better over the past year, HYPR or LUNG?
LUNG returned +1.69% over the past 12 months, compared with -55.02% for HYPR (price return, excluding dividends). Past performance does not predict future results.
Are Hyperfine and Pulmonx in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.